Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Reversible orolingual dyskinesia in a case of juvenile onset psychosis and cognitive decline.

Holla VV, Yadav R, Iyer V, Chaithra SP, Stezin A, Pal PK.

Parkinsonism Relat Disord. 2020 Jan 8. pii: S1353-8020(19)30533-4. doi: 10.1016/j.parkreldis.2019.12.014. [Epub ahead of print] No abstract available.

PMID:
31948789
2.

A novel OPTN variant causing PSP-CBS-like phenotype in familial amyotrophic lateral sclerosis.

Stezin A, Chaithra SP, Holla VV, Kamble N, Yadav R, Pal PK.

Parkinsonism Relat Disord. 2019 Dec;69:147-149. doi: 10.1016/j.parkreldis.2019.11.003. Epub 2019 Nov 9. No abstract available.

PMID:
31759189
3.

Fast Orthostatic Tremor in Parkinson's Disease: Case Report and Comprehensive Review of Literature.

Chaithra SP, Prasad S, Holla VV, Pal PK.

Tremor Other Hyperkinet Mov (N Y). 2019 Sep 16;9. doi: 10.7916/tohm.v0.704. eCollection 2019.

4.

Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology.

Zeng J, Johnson A, Shufean MA, Kahle M, Yang D, Woodman SE, Vu T, Moorthy S, Holla V, Meric-Bernstam F.

JCO Clin Cancer Inform. 2019 Sep;3:1-12. doi: 10.1200/CCI.19.00089.

5.

Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory.

Arango NP, Brusco L, Shaw KRM, Chen K, Eterovic AK, Holla V, Johnson A, Litzenburger B, Khotskaya YB, Sanchez N, Bailey A, Zheng X, Horombe C, Kopetz S, Farhangfar CJ, Routbort M, Broaddus R, Bernstam EV, Mendelsohn J, Mills GB, Meric-Bernstam F.

Oncotarget. 2019 Aug 27;10(50):5254. doi: 10.18632/oncotarget.27176. eCollection 2019 Aug 27.

6.

Asymmetric Limb Dystonia in Progressive Supranuclear Palsy: Conundrum in Nosology.

Stezin A, Holla VV, Chaithra SP, Kamble N, Saini J, Yadav R, Pal PK.

Mov Disord Clin Pract. 2019 Apr 5;6(5):415-416. doi: 10.1002/mdc3.12756. eCollection 2019 Jun. No abstract available.

PMID:
31286014
7.

OCTANE: Oncology Clinical Trial Annotation Engine.

Zeng J, Shufean MA, Khotskaya Y, Yang D, Kahle M, Johnson A, Holla V, Sánchez N, Mills Shaw KR, Bernstam EV, Meric-Bernstam F.

JCO Clin Cancer Inform. 2019 Jul;3:1-11. doi: 10.1200/CCI.18.00145.

8.

Screening of Commercial Enzymes for Transfructosylation of Tyrosol: Effect of Process Conditions and Reaction Network.

Hollá V, Antošová M, Karkeszová K, Mastihuba V, Polakovič M.

Biotechnol J. 2019 Aug;14(8):e1800571. doi: 10.1002/biot.201800571. Epub 2019 May 2.

PMID:
30927487
9.

Re-emergent Tongue Tremor in Neuroleptic-induced Parkinsonism.

Prasad S, Holla VV, Pal PK.

Tremor Other Hyperkinet Mov (N Y). 2019 Mar 6;9:632. doi: 10.7916/7ndm-gx63. eCollection 2019.

10.

Rapamycin - mTOR + BRAF = ? Using relational similarity to find therapeutically relevant drug-gene relationships in unstructured text.

Fathiamini S, Johnson AM, Zeng J, Holla V, Sanchez NS, Meric-Bernstam F, Bernstam EV, Cohen T.

J Biomed Inform. 2019 Feb;90:103094. doi: 10.1016/j.jbi.2019.103094. Epub 2019 Jan 4. No abstract available.

PMID:
30615938
11.

Untying the gordion knot of targeting MET in cancer.

Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D.

Cancer Treat Rev. 2018 May;66:95-103. doi: 10.1016/j.ctrv.2018.04.008. Epub 2018 Apr 26. Review.

PMID:
29730462
12.

Precision Oncology Decision Support: Current Approaches and Strategies for the Future.

Kurnit KC, Dumbrava EEI, Litzenburger B, Khotskaya YB, Johnson AM, Yap TA, Rodon J, Zeng J, Shufean MA, Bailey AM, Sánchez NS, Holla V, Mendelsohn J, Shaw KM, Bernstam EV, Mills GB, Meric-Bernstam F.

Clin Cancer Res. 2018 Jun 15;24(12):2719-2731. doi: 10.1158/1078-0432.CCR-17-2494. Epub 2018 Feb 2. Review.

13.

Response to Mammalian Target of Rapamycin-Based Therapy and Incidental Finding of Lynch Syndrome in a Patient With Solid Pseudopapillary Neoplasm of the Pancreas With AKT1_E17K Mutation.

Cuglievan B, Subbiah V, Wang H, Morani A, Meric-Bernstam F, Holla V, Herzog CE.

JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00182. Epub 2018 Dec 19. No abstract available.

14.

Physician interpretation of genomic test results and treatment selection.

Brusco LL, Wathoo C, Mills Shaw KR, Holla VR, Bailey AM, Johnson AM, Khotskaya YB, Litzenburger BC, Sanchez NS, Zeng J, Bernstam EV, Eng C, Kee BK, Amaria RN, Routbort MJ, Mills GB, Mendelsohn J, Meric-Bernstam F.

Cancer. 2018 Mar 1;124(5):966-972. doi: 10.1002/cncr.31112. Epub 2017 Nov 22.

15.

"Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource.

Kurnit KC, Bailey AM, Zeng J, Johnson AM, Shufean MA, Brusco L, Litzenburger BC, Sánchez NS, Khotskaya YB, Holla V, Simpson A, Mills GB, Mendelsohn J, Bernstam E, Shaw K, Meric-Bernstam F.

Cancer Res. 2017 Nov 1;77(21):e123-e126. doi: 10.1158/0008-5472.CAN-17-0341.

16.

Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature.

Korphaisarn K, Loree JM, Nguyen V, Coulson R, Holla V, Litzenburger BC, Chen K, Mills GB, Maru DM, Meric-Bernstan F, Shaw KRM, Kopetz S.

Oncotarget. 2017 Jun 3;8(34):57882-57888. doi: 10.18632/oncotarget.18357. eCollection 2017 Aug 22.

17.

Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.

Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi V, Benjamin R, Kumar Patel S, Somaiah N, Conley A, Ali SM, Schrock AB, Ross JS, Stephens PJ, Miller VA, Sen S, Herzog C, Meric-Bernstam F, Subbiah V.

Oncotarget. 2017 Jun 13;8(24):39254-39267. doi: 10.18632/oncotarget.16845.

18.

A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory.

Arango NP, Brusco L, Mills Shaw KR, Chen K, Eterovic AK, Holla V, Johnson A, Litzenburger B, Khotskaya YB, Sanchez N, Bailey A, Zheng X, Horombe C, Kopetz S, Farhangfar CJ, Routbort M, Broaddus R, Bernstam EV, Mendelsohn J, Mills GB, Meric-Bernstam F.

Oncotarget. 2017 Jun 27;8(26):41806-41814. doi: 10.18632/oncotarget.16018. Erratum in: Oncotarget. 2019 Aug 27;10(50):5254.

19.

A study of acute muscle dysfunction with particular reference to dengue myopathy.

Verma R, Holla VV, Kumar V, Jain A, Husain N, Malhotra KP, Garg RK, Malhotra HS, Sharma PK, Kumar N.

Ann Indian Acad Neurol. 2017 Jan-Mar;20(1):13-22. doi: 10.4103/0972-2327.199914.

20.

Multifocal myoclonus as a heralding manifestation of Wilson disease.

Verma R, Holla VV, Pandey S, Rizvi I.

J Pediatr Neurosci. 2016 Oct-Dec;11(4):358-360. doi: 10.4103/1817-1745.199468.

21.

Reversible opercular syndrome secondary to osmotic demyelination.

Pandey S, Holla VV, Rizvi I, Shukla R.

Clin Neurol Neurosurg. 2017 Apr;155:12-13. doi: 10.1016/j.clineuro.2017.02.001. Epub 2017 Feb 11.

PMID:
28212925
22.

Targeting TRK family proteins in cancer.

Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS.

Pharmacol Ther. 2017 May;173:58-66. doi: 10.1016/j.pharmthera.2017.02.006. Epub 2017 Feb 4. Review.

PMID:
28174090
23.

ALK: a tyrosine kinase target for cancer therapy.

Holla VR, Elamin YY, Bailey AM, Johnson AM, Litzenburger BC, Khotskaya YB, Sanchez NS, Zeng J, Shufean MA, Shaw KR, Mendelsohn J, Mills GB, Meric-Bernstam F, Simon GR.

Cold Spring Harb Mol Case Stud. 2017 Jan;3(1):a001115. doi: 10.1101/mcs.a001115. Review.

24.

Clinical Use of Precision Oncology Decision Support.

Johnson A, Khotskaya YB, Brusco L, Zeng J, Holla V, Bailey AM, Litzenburger BC, Sanchez N, Shufean MA, Piha-Paul S, Subbiah V, Hong D, Routbort M, Broaddus R, Mills Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00036. Epub 2017 Sep 13.

25.

Venous Infarcts Mimicking Large Vessel Arterial Disease: Watershed Lesions in Deep Cerebral Venous Thrombosis.

Singh RJ, Saini J, Holla VV, Kamble N.

J Stroke Cerebrovasc Dis. 2017 Feb;26(2):455-456. doi: 10.1016/j.jstrokecerebrovasdis.2016.11.014. Epub 2016 Dec 8. No abstract available.

PMID:
27939142
26.

A Study to Analyze Different Patterns of Quid Usage among Subjects with Oral Submucous Fibrosis in Mangalore Population.

Holla VA, Chatra LK, Shenai P, Shetty D, Baliga A.

Adv Med. 2016;2016:6124059. Epub 2016 Sep 29.

27.

Hirayama Disease with Periscapular Involvement: A Rare Association.

Holla VV, Kumar S, Shukla R.

Ann Neurosci. 2016 Mar;23(1):56-9. doi: 10.1159/000443557. Epub 2016 Mar 11.

28.

Paroxysmal kinesigenic dyskinesia: A frequently misdiagnosed movement disorder.

Pandey S, Holla VV, Qavi A, Shukla R.

Neurol India. 2016 Jul-Aug;64(4):792-3. doi: 10.4103/0028-3886.185413. No abstract available.

29.

Automated identification of molecular effects of drugs (AIMED).

Fathiamini S, Johnson AM, Zeng J, Araya A, Holla V, Bailey AM, Litzenburger BC, Sanchez NS, Khotskaya Y, Xu H, Meric-Bernstam F, Bernstam EV, Cohen T.

J Am Med Inform Assoc. 2016 Jul;23(4):758-65. doi: 10.1093/jamia/ocw030. Epub 2016 Apr 23.

30.

Extracting genetic alteration information for personalized cancer therapy from ClinicalTrials.gov.

Xu J, Lee HJ, Zeng J, Wu Y, Zhang Y, Huang LC, Johnson A, Holla V, Bailey AM, Cohen T, Meric-Bernstam F, Bernstam EV, Xu H.

J Am Med Inform Assoc. 2016 Jul;23(4):750-7. doi: 10.1093/jamia/ocw009. Epub 2016 Mar 24.

31.

The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform.

Johnson A, Zeng J, Bailey AM, Holla V, Litzenburger B, Lara-Guerra H, Mills GB, Mendelsohn J, Shaw KR, Meric-Bernstam F.

Drug Discov Today. 2015 Dec;20(12):1433-8. doi: 10.1016/j.drudis.2015.05.013. Epub 2015 Jul 3.

32.

A decision support framework for genomically informed investigational cancer therapy.

Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, Routbort M, Patel KP, Zeng J, Kopetz S, Davies MA, Piha-Paul SA, Hong DS, Eterovic AK, Tsimberidou AM, Broaddus R, Bernstam EV, Shaw KR, Mendelsohn J, Mills GB.

J Natl Cancer Inst. 2015 Apr 11;107(7). pii: djv098. doi: 10.1093/jnci/djv098. Print 2015 Jul. Review.

33.

Using Ontology Fingerprints to disambiguate gene name entities in the biomedical literature.

Chen G, Zhao J, Cohen T, Tao C, Sun J, Xu H, Bernstam EV, Lawson A, Zeng J, Johnson AM, Holla V, Bailey AM, Lara-Guerra H, Litzenburger B, Meric-Bernstam F, Jim Zheng W.

Database (Oxford). 2015 Apr 8;2015:bav034. doi: 10.1093/database/bav034. Print 2015.

34.

Adapting a natural language processing tool to facilitate clinical trial curation for personalized cancer therapy.

Zeng J, Wu Y, Bailey A, Johnson A, Holla V, Bernstam EV, Xu H, Meric-Bernstam F.

AMIA Jt Summits Transl Sci Proc. 2014 Apr 7;2014:126-31. eCollection 2014.

35.

Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic.

Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, Salgia R, Kurzrock R, Meric-Bernstam F, Hong DS.

Clin Cancer Res. 2014 Dec 15;20(24):6336-45. doi: 10.1158/1078-0432.CCR-14-1293. Epub 2014 Oct 17.

36.

Neurological manifestations of dengue infection: a review.

Verma R, Sahu R, Holla V.

J Neurol Sci. 2014 Nov 15;346(1-2):26-34. doi: 10.1016/j.jns.2014.08.044. Epub 2014 Sep 6. Review.

PMID:
25220113
37.

CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse models.

Kim SH, Margalit O, Katoh H, Wang D, Wu H, Xia D, Holla VR, Yang P, DuBois RN.

Invest New Drugs. 2014 Dec;32(6):1105-1112. doi: 10.1007/s10637-014-0144-z. Epub 2014 Aug 3.

38.

Synergistic therapeutic vascular cytoprotection against complement-mediated injury induced via a PKCα-, AMPK-, and CREB-dependent pathway.

Hamdulay SS, Wang B, Calay D, Kiprianos AP, Cole J, Dumont O, Dryden N, Randi AM, Thornton CC, Al-Rashed F, Hoong C, Shamsi A, Liu Z, Holla VR, Boyle JJ, Haskard DO, Mason JC.

J Immunol. 2014 May 1;192(9):4316-27. doi: 10.4049/jimmunol.1301702. Epub 2014 Mar 26.

39.

Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps.

Bailey AM, Mao Y, Zeng J, Holla V, Johnson A, Brusco L, Chen K, Mendelsohn J, Routbort MJ, Mills GB, Meric-Bernstam F.

Discov Med. 2014 Feb;17(92):101-14. Review.

40.

HIG2 promotes colorectal cancer progression via hypoxia-dependent and independent pathways.

Kim SH, Wang D, Park YY, Katoh H, Margalit O, Sheffer M, Wu H, Holla VR, Lee JS, DuBois RN.

Cancer Lett. 2013 Dec 1;341(2):159-65. doi: 10.1016/j.canlet.2013.07.028. Epub 2013 Aug 2.

41.

Unusual presentation of Kallmannn syndrome with contiguous gene deletion in three siblings of a family.

Madhu SV, Kant S, Holla VV, Arora R, Rathi S.

Indian J Endocrinol Metab. 2012 Dec;16(Suppl 2):S326-8. doi: 10.4103/2230-8210.104077.

42.

Spindle cell lipoma: a case report and review of literature.

Chandrashekhar P, Jose M, Dadhich M, Chatra L, Holla V.

Kathmandu Univ Med J (KUMJ). 2012 Apr-Jun;10(38):92-5. Review.

PMID:
23132485
43.

Prostaglandin E2 regulates pancreatic stellate cell activity via the EP4 receptor.

Charo C, Holla V, Arumugam T, Hwang R, Yang P, Dubois RN, Menter DG, Logsdon CD, Ramachandran V.

Pancreas. 2013 Apr;42(3):467-74. doi: 10.1097/MPA.0b013e318264d0f8.

44.

Bilateral inflammatory cysts of the jaw: report of an unusual case.

Holla VA, Chatra L, Shenai P, Rao PK, Veena K, Prabhu RV.

Imaging Sci Dent. 2012 Jun;42(2):105-9. doi: 10.5624/isd.2012.42.2.105. Epub 2012 Jun 25.

45.

H1N1 Newer Vaccine Usage: Experiences from Karnataka State.

Holla VN, Borker S.

Indian J Community Med. 2012 Apr;37(2):134-6. doi: 10.4103/0970-0218.96108. No abstract available.

46.

Nuclear orphan receptor NR4A2 modulates fatty acid oxidation pathways in colorectal cancer.

Holla VR, Wu H, Shi Q, Menter DG, DuBois RN.

J Biol Chem. 2011 Aug 26;286(34):30003-9. doi: 10.1074/jbc.M110.184697. Epub 2011 Jul 10.

47.

Human enhancer of filamentation 1 Is a mediator of hypoxia-inducible factor-1alpha-mediated migration in colorectal carcinoma cells.

Kim SH, Xia D, Kim SW, Holla V, Menter DG, Dubois RN.

Cancer Res. 2010 May 15;70(10):4054-63. doi: 10.1158/0008-5472.CAN-09-2110. Epub 2010 May 4.

48.

HEF1 is a crucial mediator of the proliferative effects of prostaglandin E(2) on colon cancer cells.

Xia D, Holla VR, Wang D, Menter DG, DuBois RN.

Cancer Res. 2010 Jan 15;70(2):824-31. doi: 10.1158/0008-5472.CAN-09-2105. Epub 2010 Jan 12.

49.

Regulation of prostaglandin transporters in colorectal neoplasia.

Holla VR, Backlund MG, Yang P, Newman RA, DuBois RN.

Cancer Prev Res (Phila). 2008 Jul;1(2):93-9. doi: 10.1158/1940-6207.CAPR-07-0009. Epub 2008 Mar 19.

50.

Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer.

Backlund MG, Mann JR, Holla VR, Shi Q, Daikoku T, Dey SK, DuBois RN.

Cancer Res. 2008 Nov 15;68(22):9331-7. doi: 10.1158/0008-5472.CAN-08-2893.

Supplemental Content

Support Center